FY26 Full Year Results & FY27 Guidance Investor Presentation
Resonance Health Ltd
Key points
- FY26 revenue of $15.8M, up 42% YoY
- Net profit after tax of $1.5M, a $3.2M turnaround from FY25
- Normalised EBITDA of $2.6M, up 83% YoY
- Free cash flow of $2.8M, up 148% YoY
- Strong pipeline and growth opportunities for FY27
Full summary
Resonance Health Ltd. reported full-year results for FY26, showcasing a significant improvement in financial performance. The company achieved a revenue of $15.8M, a 42% increase from FY25. This growth was driven by all three business segments: SaMD, CRO, and TrialsWest. The company returned to profitability with a net profit after tax of $1.5M, a notable turnaround from the $1.7M loss in FY25. Normalised EBITDA stood at $2.6M, up 83% from the previous year, reflecting a 16% margin. Cash flow metrics also improved, with free cash flow reaching $2.8M, a 148% increase. The company ended FY26 with $4.8M in cash and a net cash position of $2.3M, up from $0.1M in FY25. Looking ahead, Resonance Health is well-positioned to leverage macro tailwinds in liver disease prevalence, MASH diagnostics demand, and GLP-1 trial volumes, with a strong pipeline and growth opportunities for FY27.